多发性硬化残疾恶化表型及疾病修饰治疗的影响
该多中心队列研究基于意大利MS注册库,对2563例未治疗和2952例治疗的复发起病型MS患者进行分析,识别出4种残疾恶化表型(轻微恶化15%、晚期恶化70%、早期恶化3%、快速恶化12%),PIRA是各表型主要残疾累积机制,DMT暴露显著减少所有表型的残疾累积,高效DMT和早期升级对快速恶化表型尤其有益。
要点
- 未治疗MS患者可识别4种残疾恶化表型,以晚期恶化最常见(70%)。
- PIRA是所有表型残疾累积的主要机制。
- 高效DMT及早期升级对快速恶化表型获益尤其显著。
核心结论
- 复发起病型MS存在4种临床相关的残疾恶化表型,主要由PIRA驱动,更严重的中枢神经系统受累与早期和快速进展相关。
- DMT暴露显著减少所有表型的残疾累积,高效DMT和早期升级对快速恶化表型尤其有益。
研究设计与样本
- 多中心队列研究,分析意大利MS注册库中倾向匹配的治疗与未治疗复发起病型MS患者。
- 纳入标准:随访≥3年、疾病起病至首次评估≤1年、完整临床和基线MRI数据。
- 未治疗患者2563例(平均年龄41.2±10岁,67%女性),治疗患者2952例(平均年龄40.8±11.4岁,66%女性),中位随访10.1年(IQR 7.0-13.0)。
- 采用潜在类别混合模型基于未治疗患者的EDSS评分识别表型,随机森林算法(70%训练/30%测试)将表型分配给治疗患者,线性混合效应模型估计DMT对残疾轨迹的影响。
主要发现
- 未治疗患者中识别4种表型:轻微恶化15%、晚期恶化70%、早期恶化3%、快速恶化12%。
- 所有表型中PIRA是主要残疾累积机制。
- 早期恶化和快速恶化表型基线脑和脊髓T2高信号及钆增强病灶更多。
- 分类算法以71%准确率将表型分配给治疗患者:轻微恶化18%、晚期恶化61%、早期恶化13%、快速恶化8%。
- DMT暴露显著减少所有表型的残疾累积,高效DMT(β=-0.16,SE=0.06,p<0.001)和早期升级(β=-0.18,SE=0.06,p<0.001)对快速恶化表型尤其有益。
临床怎么用
- 这些表型可能有助于个性化治疗和疗效评估,尽管仅依赖EDSS。
局限性
- 研究仅依赖EDSS评估残疾恶化表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with multiple sclerosis (MS) exhibit variability in disability progression and response to disease-modifying therapies (DMTs). Identifying those at greatest risk of disability worsening and most likely to benefit from high-efficacy DMTs remains challenging. We aimed to identify distinct disability worsening phenotypes, explore their mechanisms, and evaluate DMT impact across them. METHODS: In this multicenter cohort study, we analyzed clinical and MRI data from propensity-matched cohorts of treated and untreated patients with relapse-onset MS from the Italian MS Register. Inclusion criteria were as follows: ≥3 years of follow-up, ≤1 year between disease onset and first assessment, and complete clinical and baseline MRI data. Latent class mixture models were applied to Expanded Disability Status Scale (EDSS) scores from untreated patients to identify disability worsening phenotypes. We compared proportions of progression independent of relapse activity (PIRA) and relapse-associated worsening events across phenotypes. A random forest algorithm, trained (70%) and tested (30%) on baseline clinical and MRI features of untreated patients, was used to assign phenotypes to treated patients. Linear mixed-effects models estimated DMT impact on disability trajectories within each phenotype. RESULTS: We analyzed data from 2,563 untreated (mean age 41.2 ± 10 years, 67% female) and 2,952 treated (mean age 40.8 ± 11.4 years, 66% female) patients with MS over a median follow-up of 10.1 (interquartile range: 7.0-13.0) years. Four phenotypes were identified in untreated patients: "minimal-worsening" (15%), "late-worsening" (70%), "early-worsening" (3%), and "rapid-worsening" (12%). In all phenotypes, PIRA represented the main disability accrual mechanism. "Early-worsening" and "rapid-worsening" phenotypes exhibited more brain and spinal cord T2-hyperintense and gadolinium-enhancing lesions at baseline. The classification algorithm assigned phenotypes to patients receiving DMTs with 71% accuracy: "minimal-worsening" (18%), "late-worsening" (61%), "early-worsening" (13%), and "rapid-worsening" (8%). DMT exposure significantly reduced disability accrual in all phenotypes, with high-efficacy DMTs (β = -0.16, standard error (SE) = 0.06, p < 0.001) and early escalation (β = -0.18, SE = 0.06, p < 0.001) proving especially beneficial for the "rapid-worsening" phenotype. DISCUSSION: We identified 4 clinically relevant disability worsening phenotypes in relapse-onset MS, primarily driven by PIRA, with greater CNS involvement linked to early and rapid progression. Despite reliance on EDSS alone, these phenotypes may inform personalized treatment and response assessment.
引用
- De Meo E, Addazio I, Portaccio E, et al. Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments. Neurology. 2025. PMID: 41284953. doi:10.1212/WNL.0000000000214408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。